Research programme: adenosine A3 antagonists - Addex Pharmaceuticals

Drug Profile

Research programme: adenosine A3 antagonists - Addex Pharmaceuticals

Alternative Names: Adenosine A3 orthosteric antagonists - Addex

Latest Information Update: 14 Aug 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Addex Pharmaceuticals
  • Developer Addex Therapeutics
  • Class
  • Mechanism of Action Adenosine A3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes - Glaucoma

Highest Development Phases

  • Discontinued Glaucoma

Most Recent Events

  • 16 Jul 2009 This adenosine A3 antagonist programme is available for licensing (
  • 16 Jul 2009 Discontinued - Preclinical for Glaucoma in Switzerland (unspecified route)
  • 29 Jan 2009 Preclinical trials in Glaucoma in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top